• Our Mission
• Company Headquarters
• History
• Awards and Recognition
• Press Releases

LacPro is an innovative probiotic biotechnology company, focused on researching, developing, and commercializing medical food and biotherapeutic products to address unmet or insufficiently addressed health care needs. Initially, our efforts target gastrointestinal (GI) ailments, including Clostridium difficile Infection (CDI), Inflammatory Bowel Disease (IBD), and Irritable Bowel Syndrome (IBS).

Our first product was introduced October 20008, at the American Dietetic Association’s Food and Nutrition Conference and Expo (ADA/FNCE). This medical food product, Antibiotic Assist™ is based upon our proprietary and beneficial probiotic technology that provides relief from symptoms, enhances GI tract health, and reduces the occurrence of infections for patients and long-term care residents prescribed antibiotic therapies, which often result in antibiotic-associated diarrhea, specifically Clostridium difficile infection.

Our mission is to be the world’s leading probiotic biotechnology company, discovering, developing, and commercializing medical foods and biotherapeutics that address unmet or insufficiently addressed health care needs. We seek solutions that enhance the well-being of patients and long-term care residents, improve medical outcomes, and reduce total health care expenditures. As a corporation, we seek significant returns to our shareholders, based on the continued pursuit of scientific and operational excellence.

Back To Top

LacPro Industries is headquartered in Fort Wayne, Indiana, LacPro recently graduated from the Northeast Indiana Innovation Center (NIIC) and relocated its base of operations to the rennovated historic Falstaff building in downtown Ft. Wayne; joining a growing number of former NIIC clients in the for Fort Wayne, business community.

LacPro benefits from Indiana’s focus and support on the life sciences. Indiana is one of the nation's top four life sciences leaders (as defined by number and concentration of life sciences-related jobs), according to the report, "Growing the Nation's Bioscience Sector: State Bioscience Initiatives 2006" (Battelle Memorial Institute).

Indiana has long been a world leader in life sciences and home to such industry giants as Eli Lilly and Company, Biomet, Cook Group, Inc. and Zimmer. Indiana boasts the second largest medical school in the U.S. (Indiana University School of Medicine). Indiana's life sciences industry succeeds through a collaboration of partnerships between industry, academia and government.

Back To Top

LacPro was founded in 1998 by Dr. Gregory G. Bojrab, a Fort Wayne native and practicing internist, when he was diagnosed with ulcerative colitis (UC). His gastroenterologist treated him with first line anti-inflammatory agents, which were ineffective and, paradoxically, worsened his condition.

While the exact cause of UC was and remains unknown, a growing body of research indicated an altered bowel flora played some role in the development of the disease. Yet, most research was directed toward improving agents to block the inflammatory response rather than correcting the ecologic imbalance. However, it seemed reasonable to Dr. Bojrab that UC could be treated by a probiotic that corrected the altered bowel flora, if the right strain(s) were found. While several attempts were made to treat his condition with commercially available yogurts, none proved to be effective.

Fortuitously, Dr. Bojrab identified and isolated a functional strain and developed a single strain fermented beverage that not induced a remission, but daily use has maintained remission for 9 years.

Surprising and consistent success was also observed in patients with antibiotic-associated diarrhea, including Clostridium difficile Infection, even those who had not responded to traditional therapies.

Based on his personal success as well as the success of his patients, Dr. Bojrab recognized the significance of the product to safely and naturally resolve, and possibly prevent, a variety of gastrointestinal ailments. Thus, in October 2005, the company formally launched operations to research, develop and commercialize medical foods and biotherapeutics based on the company’s proprietary probiotic strain.

Back To Top